Jay A. Levy, MD

Jay A. Levy, MD

Professor in Residence, Department of Medicine, UCSF


Phone: (415) 476-4071 (voice)
Box 1270, UCSF
San Francisco, CA 94143-1270

View on UCSF Profiles

Cancer Center Membership

Associate Member ยป Cancer, Immunity, and Microenvironment


Wesleyan University, Middletown, CT, BA, 1960, Biology
Universite de Paris, France, 1961, Regeneration
Columbia University, New York, MD, 1965, Medicine and Virology

Professional Experience

  • 1965-1966
    Intern in Medicine, Hospital of the University of Pennsylvania
  • 1966-1967
    First year resident in Medicine, Hospital of the University of Pennsylvania
  • 1967-1970
    Staff Associate,National Cancer Institute, NIH, Bethesda, MD
  • 1970-1971
    Second year resident, University of California, San Francisco (UCSF)
  • 1971-1972
    Visiting Scientist, Hopital St. Louis (Prof. M. Boiron), Paris; Hopital Paul-Brousse (Dr. G. Mathe), ICIG, Paris
  • 1972-1977
    Assistant Professor of Medicine, Research Associate, Cancer Research Institute, University of California San Francisco
  • 1978-1979
    Visiting Scientist, Weizmann Institute, Rehovot, Israel (Prof. N. Haran-Ghera); Pasteur Institute, Paris (Prof. F. Jacob)
  • 1978-1985
    Associate Professor of Medicine, and Microbiology and Immunology, University of California San Francisco
  • 1985-present
    Professor, Dept of Med., Div of Hem/Onc and Research Assoc, Cancer Research Institute, UCSF

Selected Publications

  1. AIDS new editor announcement. AIDS. 2016 Jan; 30(2):165.
    View on PubMed
  2. Discovery of another anti-HIV protein in the search for the CD8+ cell anti-HIV Factor. Proc Natl Acad Sci U S A. 2015 Jun 30; 112(26):7888-9.
    View on PubMed
  3. Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects. Hum Vaccin Immunother. 2015 Jun 3; 11(6):1540-56.
    View on PubMed
  4. Dispelling myths and focusing on notable concepts in HIV pathogenesis. Trends Mol Med. 2015 Jun; 21(6):341-53.
    View on PubMed
  5. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5?32 mutation confers resistance to HIV infection. Proc Natl Acad Sci U S A. 2014 Jul 1; 111(26):9591-6.
    View on PubMed
  6. Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits. Clin Vaccine Immunol. 2014 Aug; 21(8):1086-93.
    View on PubMed
  7. Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects. J Virol. 2013 Sep; 87(18):10004-15.
    View on PubMed
  8. Nevirapine inhibits the anti-HIV activity of CD8+ cells. J Acquir Immune Defic Syndr. 2013 Jun 1; 63(2):184-8.
    View on PubMed
  9. Plasmacytoid dendritic cell number and responses to Toll-like receptor 7 and 9 agonists vary in HIV Type 1-infected individuals in relation to clinical state. AIDS Res Hum Retroviruses. 2013 Mar; 29(3):501-10.
    View on PubMed
  10. AIDS and HIV Infection after Thirty Years. AIDS Res Treat. 2013; 2013:731983.
    View on PubMed
  11. HIV-1 Vaccine Trials: Evolving Concepts and Designs. Open AIDS J. 2012; 6:274-88.
    View on PubMed
  12. HIV infection: what should be considered in approaches for a cure? AIDS. 2012 Nov 13; 26(17):2253-5.
    View on PubMed
  13. HIV-related symptoms and patient clusters among Chileans living with HIV. AIDS Care. 2013; 25(4):488-95.
    View on PubMed
  14. 25 Years of AIDS: recording progress and future challenges. AIDS. 2012 Jun 19; 26(10):1187-9.
    View on PubMed
  15. Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral epithelia. J Virol. 2012 Mar; 86(5):2556-70.
    View on PubMed
  16. HIV/AIDS: 30 years of progress and future challenges. Eur J Immunol. 2011 Dec; 41(12):3401-11.
    View on PubMed
  17. Transfection optimization for primary human CD8+ cells. J Immunol Methods. 2011 Sep 30; 372(1-2):22-9.
    View on PubMed
  18. No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science. 2011 Jul 1; 333(6038):94-7.
    View on PubMed
  19. Virus-host interactions in HIV pathogenesis: directions for therapy. Adv Dent Res. 2011 Apr; 23(1):13-8.
    View on PubMed
  20. Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis. 2011 Feb 15; 203(4):442-51.
    View on PubMed

Go to UCSF Profiles, powered by CTSI